Focus: Route 92 Medical is a public medical device company specializing in catheter technology for acute ischemic stroke treatment. The company operates in the high-stakes neurology intervention market with a focused product portfolio.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Growing — net +5 jobs in 30d
14 jobs added vs 9 removed. Steady team buildout.
Route 92 Medical suits professionals seeking commercial-stage medical device experience in a focused therapeutic area with limited long-term growth runway.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Lead product in Phase 4 with single active trial indicating post-approval stage and commercial scaling.
Help build intelligence for Route 92 Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Route 92 Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
The novel Tenzing 7 delivery catheter designed to deliver intermediate catheters to the face of embolus without crossing: clinical performance predicted in anatomically challenging model.
Preventing vessel perforations in endovascular thrombectomy: feasibility and safety of passing the clot with a microcatheter without microwire: the wireless microcatheter technique.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo